Ziel
NANOFOL proposes to develop a new diagnostic/therapy approach using folate based nanobiodevices (FBN) able to provide a new type of cost efficient treatment for chronic inflammatory diseases such as Atherosclerosis and Rheumatoid Arthritis with low side effects that will constitute a more advantageous solution than current therapies. NANOFOL will achieve all that by fulfilling the following objectives: •Design , development and production of nanobiodevices (FBN) targeting directly effector cells •Proof of concept in vitro and in vivo of a folate based nanodevice targeting activated macrophages in chronic inflammation not affecting bystander cells •Proof of concept in vitro and in vivo of a nanodevice containing a bispecific antibody (against folate receptor and another macrophage marker) targeting activated macrophages in chronic inflammation not affecting bystander cells •Proof of concept of FBN delivery therapeutic agents (by small interfering ribonucleic acid molecules (siRNA) or lipophylic molecules) targeting inflammatory signaling pathways •In vitro and in vivo testing of cellular toxicity caused by the novel nanobiodevices in cells other than activated macrophages •Design of models that will enable to minimize animal experimentation. •Development of a strategy to assess potential risks in order to ensure nanobiodevice safe delivery. NANOFOL has adopted a specific risk strategy to attain objectives in a step by step approach allowing improving gradually the concept (specificity, stability, side effects efficacy) from the lower to the higher risky solutions ensuring reduced experimental animal testing and high human safety. The NANOFOL project will combine expertise in nanotechnologies, biology, chemistry, materials science, biotechnology, engineering, risk analysis, medical and pharmaceutical sciences.
Wissenschaftliches Gebiet
Programm/Programme
Aufforderung zur Vorschlagseinreichung
FP7-NMP-2008-LARGE-2
Andere Projekte für diesen Aufruf anzeigen
Finanzierungsplan
CP-IP - Large-scale integrating projectKoordinator
4704 553 Braga
Portugal
Auf der Karte ansehen
Beteiligte (13)
28108 Alcobendas
Auf der Karte ansehen
Beteiligung beendet
8010 Graz
Auf der Karte ansehen
2595 DA Den Haag
Auf der Karte ansehen
4200 135 Porto
Auf der Karte ansehen
75654 Paris
Auf der Karte ansehen
1090 Wien
Auf der Karte ansehen
310130 Arad
Auf der Karte ansehen
72076 Tuebingen
Auf der Karte ansehen
60550 Verneuil En Halatte
Auf der Karte ansehen
25242 VESTEC
Auf der Karte ansehen
92300 Levallois-Perret
Auf der Karte ansehen
Beteiligung beendet
2780-157 Oeiras
Auf der Karte ansehen
1180 Wien
Auf der Karte ansehen